Sunday, December 26, 2021

No Supply Issues With Ivermectin: Pharmaceutical Supplying PRINCIPLE Oxford Trial

The New Jersey pharmaceutical company supplying ivermectin to a UK trial that was paused for a short period of time, says there are no supply issues with its pills.

Daniel Worley Jr., Vice President of Business Development and Associate General Counsel of Edinbridge Pharmaceuticals, the manufacturer supplying the medicine, told The Epoch Times in an email that the company "Is not experiencing any supply issues related to its ivermectin tablets product."

The company's ivermectin tablets were added to the World Health Organization's Prequalified Medicines List last year in September, which ensures that a medicine meets "Acceptable standards of quality, safety, and efficacy" for international procurement agencies to purchase and distribute in "Resource-limited countries." The list is part of the United Nation's Prequalification of Medicines Programme and is run by the WHO. The halt on the trial has since been lifted as of Friday.

When PRINCIPLE announced its ivermectin trial in June 2021, Butler, the co-chief investigator, said the drug was safe and readily available, suggesting that there was an appropriate supply of the drug.

Several doctors questioned the sudden pause on the PRINCIPLE trial as a result of the ivermectin supply.

"Either they're grossly incompetent at the University of Oxford or lying. It's one or the other because [the] worldwide supply of ivermectin is enormous, and there's no way that a competent clinical research team would not have locked down their trial supply."

World-known French toxicologist, Prof. Jacques Descotes, in his comprehensive assessment of the safety profile of ivermectin based on an analysis of more than 350 articles, concluded that "The safety profile of ivermectin has so far been excellent in the majority of treated human patients so that ivermectin human toxicity cannot be claimed to be a serious cause for concern."

https://www.theepochtimes.com/no-supply-issues-with-ivermectin-pharmaceutical-supplying-principle-oxford-trial_4177066.html 

No comments: